Trial of PDE4 Inhibition With Roflumilast for the Management of Seborrheic Dermatitis (STRATUM)

  • End date
    May 11, 2022
  • participants needed
  • sponsor
    Arcutis Biotherapeutics, Inc.
Updated on 11 September 2021


The study will assess the safety and efficacy of ARQ-154 foam vs vehicle applied once for 8 weeks by subjects with seborrheic dermatitis.


This is a parallel group, double blind, vehicle-controlled study in which ARQ-154 foam or vehicle is applied once daily for 8 weeks to subjects with seborrheic dermatitis.

Condition Seborrheic dermatitis, Dermatitis
Treatment ARQ-154 - Active, ARQ-154 Vehicle
Clinical Study IdentifierNCT04973228
SponsorArcutis Biotherapeutics, Inc.
Last Modified on11 September 2021


Yes No Not Sure

Inclusion Criteria

Participants legally competent to sign and give informed consent and, if appropriate, assent as required by local laws
Males and females ages 9 years and older at the time of consent
Clinical diagnosis of seborrheic dermatitis of at least 3 months duration at Screening as determined by the Investigator. Stable disease for the past 4 weeks
Seborrheic dermatitis up to 20% BSA involvement. Involvement may be of the scalp and/or face and/or trunk and/or intertriginous areas
An Investigator Global Assessment (IGA) disease severity of at least Moderate ('3') at Baseline
Overall Assessment of Erythema and Overall Assessment of Scaling scores of at least Moderate ('2') at Baseline
Females of childbearing potential (FOCBP) must have a negative serum pregnancy test at Screening (Visit 1) and a negative urine pregnancy test at Baseline (Visit 2)
Females of non-childbearing potential must either be post-menopausal with spontaneous amenorrhea for at least 12 months or have undergone surgical sterilization
Subjects in good health as judged by the Investigator
Subjects are considered reliable and capable of adhering to the Protocol and visit schedule according to the Investigator judgment

Exclusion Criteria

Subjects who cannot discontinue treatment with therapies for the treatment of seborrheic dermatitis prior to the Baseline visit and during the study
Planned excessive exposure of treated area(s) to either natural or artificial sunlight, tanning bed or other LED
Previous treatment with ARQ-154 or ARQ-151
Subjects with any serious medical condition or clinically significant abnormality that would prevent study participation or place the subject at significant risk, as judged by the Investigator
Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding
Subjects with a history of chronic alcohol or drug abuse within 6 months prior to Screening
Subjects, parent(s)/legal guardian(s) who are unable to communicate, read, or understand the local language(s)
Subjects who are family members of the clinical study site, clinical study staff, or sponsor, or family members living in the same house of enrolled subjects
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note